Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock
December 11 2019 - 10:32PM
Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology
company, today announced the pricing of its previously announced
underwritten public offering of 4,860,000 shares of its common
stock at a price to the public of $35.00 per share. Gross
proceeds to Forty Seven from the offering are expected to be $170.1
million, before deducting underwriting discounts and commissions
and estimated offering expenses. All of the shares of common
stock are being offered by Forty Seven. In addition, Forty Seven
has granted the underwriters a 30-day option to purchase up to
729,000 of additional shares of common stock at the public offering
price, less underwriting discounts and commissions. The
offering is expected to close on December 16, 2019, subject to
customary closing conditions.
Morgan Stanley & Co. LLC and Credit Suisse Securities (USA)
LLC are acting as joint book-running managers, Guggenheim
Securities, LLC and Oppenheimer & Co. Inc. are acting as lead
managers and JonesTrading Institutional Services LLC and Roth
Capital Partners, LLC are acting as co-managers for the
offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC), and was declared effective. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
have been filed with the SEC and are available on the SEC’s
website, located at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus related to the offering
may be obtained, when available, from Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, Second Floor,
New York, New York 10014; or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, Eleven Madison Avenue, Third
Floor, New York, New York 10010, by telephone at (800) 221-1037 or
by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contact
Hannah Deresiewicz – IR contact, Forty Seven,
Inc.Stern Investor Relations
Inc.hannah.deresiewicz@sternir.com(212) 362-1200
Forty Seven (NASDAQ:FTSV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forty Seven (NASDAQ:FTSV)
Historical Stock Chart
From Oct 2023 to Oct 2024